Ligand-based virtual screening

What is ligand-based virtual screening?

Ligand-based virtual screening (LBVS) is a computational method for ranking compounds using evidence from known ligands rather than the three-dimensional structure of a biological target. Common methods compare fingerprints, descriptors, shapes, pharmacophore features, molecular fields, or learned representations. A high rank means similar under the selected representation and metric; it does not prove shared activity or mechanism.

LBVS begins with reference quality. Structures, assay definitions, activity values, stereochemistry, and chemical diversity determine which region of chemical space the search can recognize. Two-dimensional fingerprints are fast and interpretable, while three-dimensional or learned representations may capture different relationships but introduce conformer, training-domain, or model uncertainty.

The method differs from structure-based screening because it does not evaluate complementarity to a receptor pocket or generate a target-specific pose. Similarity values also have no universal activity threshold: a cutoff depends on the fingerprint, metric, references, and library. Activity cliffs make close analogs especially important to inspect rather than automatically promote.

When to use ligand-based virtual screening

• Known active ligands are available. Use one or more experimentally supported reference compounds to search a broader candidate library.
• The target structure is missing or unreliable. Prioritize compounds without relying on a receptor conformation or a defined docking site.
• You need a fast first-pass ranking. Apply inexpensive descriptors or fingerprints before slower structure-based calculations and experiments.

Benefits of ligand-based virtual screening

• Works without a target structure. Known ligands can support screening when a receptor model is unavailable, incomplete, or unsuitable for docking.
• Scales efficiently to large libraries. Two-dimensional fingerprints and compact descriptors are comparatively inexpensive to calculate and compare.
• Supports several kinds of similarity. A program can compare substructures, topological fingerprints, physicochemical properties, pharmacophore features, fields, or shape.
• Makes reference assumptions explicit. Every ranking can retain the reference ligand, representation, metric, and threshold used to produce it.

Primary limitations

• The method inherits bias from known ligands. A narrow or chemically repetitive reference set can steer the search toward familiar scaffolds and miss different active chemotypes.
• Similar molecules can behave differently. Small structural changes can produce activity cliffs, alter selectivity, or change exposure and toxicity.
• Results depend on molecular representation. Different fingerprints, descriptors, conformations, feature definitions, and similarity metrics can rank the same library differently.
• Activity data require careful curation. Mixed assay formats, uncertain measurements, salts, stereochemistry, and inconsistent identifiers can weaken the reference evidence.
• Experimental validation remains necessary. Similarity supports prioritization but does not establish binding, mechanism, potency, selectivity, safety, or efficacy.

Ligand-based virtual screening methods

Each representation encodes a different notion of molecular resemblance. Compare methods on held-out chemistry and retain the representation and parameters behind every score.

• Two-dimensional fingerprints. Compare circular fingerprints such as Morgan or key-based fingerprints such as MACCS with a defined similarity coefficient.
• Descriptor and field methods. Rank candidates by physicochemical profiles or molecular interaction fields when topology alone is not the intended similarity concept.
• Three-dimensional ligand methods. Use shape or pharmacophore feature arrangements when a credible bioactive conformation and adequate conformer coverage are available.
• Learned representations. Apply validated embeddings or predictive models while keeping training provenance, applicability domain, and uncertainty explicit.

Ligand-based virtual screening applications

LBVS can expand around validated hits, retrieve analogs from purchasable libraries, seek scaffold-diverse neighbors with alternative representations, and prefilter a large collection before docking or assays. Multiple references can represent distinct chemotypes or activity profiles.

The method is less suitable when reference activity is uncertain, assays are mixed without harmonization, or the program seeks chemistry outside the domain represented by known ligands. Inactive data and counterexamples are particularly valuable when evaluating whether a ranking enriches the intended phenotype.

How to do ligand-based virtual screening online

ProteinIQ currently provides a review workflow around externally ranked similarity results. It calculates Morgan and MACCS fingerprints for inspection but does not yet perform the library-versus-reference Tanimoto search itself.

1. Curate reference evidence. Choose relevant active and inactive ligands, reconcile identifiers and structures, and preserve comparable assay context.
2. Standardize the library. Apply one documented policy for salts, charges, tautomers, stereochemistry, duplicates, and invalid inputs.
3. Select and validate the representation. Choose fingerprints, descriptors, shape, pharmacophore, or learned features and test them on held-out compounds.
4. Rank with the external similarity method. Keep the matched reference, native score, metric, parameters, and aggregation rule for every candidate.
5. Review the ranked set in ProteinIQ. Compare fingerprints, molecular properties, alerts, predicted endpoints, chemical neighborhoods, and failures.
6. Export a diverse shortlist. Select compounds across credible chemotypes and validate them with orthogonal target-aware evidence and experiments.

How to interpret ligand-similarity rankings

A Tanimoto or other similarity value is meaningful only with its fingerprint and reference set. Do not compare thresholds across representations as though they share one scale, and keep reference-specific scores visible when several actives are used.

Inspect close neighbors for activity cliffs, assay changes, stereochemical differences, reactive groups, and property shifts. The most useful shortlist may include lower-ranked but structurally diverse candidates that test whether the inferred structure–activity relationship generalizes.

How ligand-based virtual screening works

LBVS starts with reference evidence. The quality of the actives, molecular standardization, selected representation, similarity metric, and diversity strategy determine what the ranking means.

1. Curate reference ligands. Choose experimentally supported actives, reconcile structures and identifiers, and keep assay context and activity values attached.
2. Standardize the library. Normalize structures consistently, preserve compound identifiers, and document how salts, charges, tautomers, and duplicates are handled.
3. Calculate molecular representations. Generate the fingerprints, descriptors, pharmacophore features, conformers, or learned embeddings required by the selected method.
4. Rank by similarity. Compare candidates with one or more references using a predefined metric and retain reference-specific scores.
5. Review and export a diverse shortlist. Inspect neighbors, properties, liabilities, scaffold diversity, and model applicability before selecting compounds for follow-up.

Inputs and outputs

Check formats before running, then inspect and download the result from every workflow step.

Inputs

• Reference ligands. SMILES SDF CSV Provide one or more reviewed ligands with stable identifiers and, when available, comparable activity measurements and assay context.
• Candidate library. SMILES SDF Use standardized compounds with stereochemistry and identifiers preserved throughout representation, ranking, and export.
• Similarity method. Define the representation, metric, reference aggregation rule, score direction, and shortlist or diversity criteria before screening.

Outputs

• Similarity ranking. CSV JSON Retain each candidate’s score, matched reference, representation, metric, and rank.
• Descriptors or fingerprints. CSV JSON Export calculated features and failures so the ranking can be reviewed and reproduced.
• Diverse shortlist. SMILES SDF CSV Keep selected structures connected to similarity evidence, property review, alerts, and diversity groups.
• Run record. LOG FILES Retain preparation rules, reference data, method settings, warnings, and exported files.